GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Total Tax Payable

CG Oncology (CG Oncology) Total Tax Payable : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Total Tax Payable?

CG Oncology's Total Tax Payable for the quarter that ended in Mar. 2024 was $0.00 Mil.

CG Oncology Total Tax Payable Historical Data

The historical data trend for CG Oncology's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Total Tax Payable Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
Total Tax Payable
- - -

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Total Tax Payable Get a 7-Day Free Trial - - - - -

CG Oncology Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

CG Oncology Total Tax Payable Related Terms

Thank you for viewing the detailed overview of CG Oncology's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Total Tax Payable
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024